Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW

• Should RA Patients with Controlled Disease Taper Methotrexate from Targeted The…

> 50% of SLE pts showed activation of all 3 complement pathways. The most frequent patterns were normal CL, low AL, normal MBL; low CL & AL, normal MBL. Dz activity, not damage, assoc'd only w/low CL and AL, and normal MBL. Abs 0317 #ACR22 @RheumNow https://t.co/nXtuZCfKDI

• Full Characterization of the Three Pathways of Complement System in Patients wi…

Leng et al. 52 week results tocilizumab biosimilar vs originator in RA. Shocker, it's the same. @RheumNow #ACR22 Abstr#0917 https://t.co/5JAoGBRzUi https://t.co/7zCUNcdzbp

• Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-control…

Proliferative LN assoc'd w/ higher risk of IFTA progression, suggesting that glomerular damage is one of the major drivers of IFTA progression in SLE. Abs 0319 #ACR22 @RheumNow https://t.co/CgdXhDBk3e https://t.co/AOZ1DnH6Sk

• Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupu…

Package insert for avacopan has a lot of monitoring requirements, including liver risk, but that seems to be relatively small (2 events per 100 pt-yrs vs pred). Other risks actually favorable as compared to pred How are others monitoring LFTs? #ACR22 @RheumNow #1077 https://t.co/VFHCpkQMWN

Kim et al. KOBIO study retention rates b/tsDMARDs in RA-ILD. Lower than in RA without ILD. Smoking (OR 5.2) steroids (OR 0.3) influence. JAKi>tocilizumab>abatacept>TNFi @RheumNow #ACR22 Abstr#0920 https://t.co/ht7IFP7VJe https://t.co/Ul93kcdP5N

• Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying A…

#ACR22 Abstr#0823 A systematic review which included 36 case series/report showed pulmonary manifestations are common in #VEXAS 56%. Unclear if due to VEXAS or previous disease which was misclassified. Longitudinal study with accurate & timely diagnosis could help @RheumNow https://t.co/ZJvmK2FWrI

Differentiation in UCTD? Abs 0328 finds puffy fingers, abnormal nailfold changes & SSc specific antibodies most predictive for UCTD progression to SSc. Younger age, serositis, +anti-dsDNA antibodies important for progression to SLE. #ACR22 @RheumNow https://t.co/DWL3V3dbFg https://t.co/fYHPOPdzfq

• Predicting Progression from Undifferentiated to Definitive Connective Tissue Di…

Roongta et al. Small RCT of MTX+LEF vs MTX+RTX in RA. 21 patients each arm. No significant difference. @RheumNow #ACR22 Abstr#0931 https://t.co/jNDrMkkvhP https://t.co/dkfUnh5SM3

• Rituximab versus Leflunomide in Combination with Methotrexate in Patients with …

Sulli et al. Concommittent folic acid delays MTX response, leads to greater doses of steroids and MTX. But more AEs when MTX without folic acid 32 vs 16% - nausea, transaminase elevations. @RheumNow #ACR22 Abstr#0930 https://t.co/jsUYG2YIZL https://t.co/YOpUbA4Ze9

• Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Rec…

IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study ◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline ◦ associated with improved BASFI, fatigue, SF36 Ramiro S Abs1009 https://t.co/GiCqg7W9IR #ACR22 @RheumNow

• Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixe…

Occupational inhaled agents increased risk of CCP+ RA, per Swedish occ data (OR 1.25, [1.12-1.38]). Dose-dependent increase in risk. Agents include quartz, asbestos, fungicides & carbon monoxide. This is a common pt question! @RheumNow ABST0601 #ACR22 https://t.co/QbsSLIXNar

• Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthri…

Park et al. MTX discontinuation for 1 week post-influenza vaccine non-inferior to 2 week hold. Higher flare rate with 2 week hold. @RheumNow #ACR22 Abstr#0936 https://t.co/G53mcWFK2C https://t.co/VFY9TS5OIv

• Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on…

Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs P Mease on BE MOBILE 1 & 2 BKZ 160 mg q4w vs PBO 254 pts w nr-axSpA, 332 w AS Improvement in spinal pain, nocturnal pain, morning stiffness, FACIT-FATIGUE for pts with AS and nr-axSpA, statistically signif diff at WK 16 @RheumNow https://t.co/nxZFSrb2XK

Ab1044 #ACR22 Combined Biologic or Targeted Therapy (CBTT) in SpA 31 CBTT courses in 29 SpA pts - 69% also w IBD Most common: TNF+IL12/23 or IL17 12 pts (38%) d/c CBTT - 7 inefficacy (5 2/2 IBD), 2 for AEs, 3 for other causes. 2 serious AEs (pulm infiltrates, staph ifn) @RheumNow https://t.co/zExkpam0zK